Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 12/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3905943 | 0.85 | TP53 (0.40) | CCR3CYP2D6 | |
| SCHEMBL3914367 | 0.82 | KCNH2 (0.35) | CYP2D6LMNAMEN1KMT2A | |
| SCHEMBL3910510 | 0.82 | POLB (0.37) | CYP2D6LMNA | |
| SCHEMBL2900410 | 0.81 | ALDH1A1 (0.40) | CYP2D6LMNA | |
| SCHEMBL3903992 | 0.80 | TP53 (0.43) | CYP2D6LMNAMEN1KMT2A | |
| SCHEMBL3905591 | 0.80 | TP53 (0.41) | MEN1KMT2A | |
| SCHEMBL3902851 | 0.80 | MCHR1 (0.42) | MEN1KMT2A | |
| SCHEMBL3905517 | 0.78 | TP53 (0.39) | MEN1KMT2A | |
| SCHEMBL3910459 | 0.75 | TP53 (0.42) | CCR3CYP2D6LMNAMEN1KMT2A | |
| SCHEMBL2891923 | 0.75 | TP53 (0.39) | CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | claimed |
| EP-1549315-A4 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | claimed |
| EP-1549315-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004024078-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | claimed |
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1153013-B1 | 5-HT1F AGONISTS | LILLY CO ELI (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1549315-A4 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| EP-1549315-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-6777428-B1 | INHIBIT PEPTIDE EXTRAVASATION DUE TO STIMULATION OF THE TRIGEMINAL GANGLIA, AND ARE THEREFORE USEFUL FOR THE TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS | ELI LILLY AND COMPANY | 2004-08-17 | — | — | US | disclosed |
| WO-2004024078-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | DHPS, DUT, CDKN1A | CCR3 817/4885CYP2D6 277/4885LMNA 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.